Japan’s Ministry of Health, Labour and Welfare (MHLW) has officially approved the Biostar Stem Cell Technology Research Institute’s innovative angel stem cell therapy aimed at treating autism spectrum disorder (ASD).
This regulatory endorsement marks a pivotal advancement in therapeutic options for individuals living with ASD in Japan.
With this approval, Biostar is now authorized to offer its angel stem cell therapy within the country, following a comprehensive review by the MHLW.
The treatment utilizes cutting-edge stem cell technology designed to alleviate symptoms associated with autism spectrum disorder.
However, specific details concerning the clinical trial data or evidence underpinning the ministry’s decision remain undisclosed.
READ MORE
- AI Tool ‘StellarCare AI’ Aids Early Autism Detection, Diagnosis at 18 Months
- New Study Reveals 4 Biologically Distinct Autism Types for Health
- Vitamin D3 Nanoemulsion Shows Promise for Easing Autism Symptoms in Kids
